Company: AZN
Filing Date: 2025-05-06
Form Type: 6-K
Source: 0001654954-25-005099
Chunk: 4

Company: ASTRAZENECA PLC
Filing Date: 2025-05-06
Form: 6-K
Chunk 4
---
 of patients worldwide. Please visit astrazeneca.com and follow the Company on Social Media @ AstraZeneca .

#### Contacts
For details on how to contact the Investor Relations Team, please click here . For Media contacts, click here .

#### References
1. Lymphoma Research Foundation. Mantle Cell Lymphoma. Available at: https://lymphoma.org/aboutlymphoma/nhl/mcl/ . Accessed April 2025.

2. National Organization for Rare Disorders. Mantle Cell Lymphoma. Available at: https://rarediseases.org/rare-diseases/mantle-cell-lymphoma/ . Accessed April 2025.

3. AstraZeneca 2024. Q3 2024 Financial Results. Available at: https://www.astrazeneca.com/investor-relations.html . Accessed April 2025.

4. Cheah C, Seymour J, Wang ML. Mantle cell lymphoma. J Clin Oncol . 2016;34(11):1256-1269. doi: 10.1200/JCO.2015.63.5904.

5. Lynch DT, Koya S, Acharya U, et al. Mantle Cell Lymphoma. Available at: https://www.ncbi.nlm.nih.gov/books/NBK536985/ . Accessed April 2025.

6. ClinicalTrials.gov. A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL. Available at: https://clinicaltrials.gov/study/NCT02972840. Accessed April 2025.

7. Wu J, et al. Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor. J Hematol Oncol . 2016;9(21).

#### Matthew Bowden

#### Company Secretary

#### AstraZeneca PLC
<div align='center'>SIGNATURES</div>

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

| AstraZeneca 
 PLC         |

Date: 06 May 2025

| By: /s/           
 Adrian Kemp       |
| Name:             
 Adrian Kemp       |
| Title:            
 Company Secretary |